Johnson & Johnson ZYTIGA — Percent Change (as a percent) decreased by 24.7% to -75.2% in Q3 2025 compared to the prior quarter. Year-over-year, this metric grew by 38.9%, from -123.1% to -75.2%. This decline may warrant attention — for this metric, higher values are generally preferred.
A positive percentage indicates growth in product sales, while a negative percentage signals a decline in market share or demand, often reflecting the impact of competition or product lifecycle maturity.
This metric measures the period-over-period percentage growth or decline in net sales for the ZYTIGA product line. It pr...
Comparable to product-level revenue growth rates reported by peers, which are essential for benchmarking the performance of specific drug franchises.
jnj_segment_zytiga_percent_change_as_a_percent| Q2 '21 | Q3 '21 | Q4 '21 | Q2 '22 | Q3 '22 | Q4 '22 | Q2 '23 | Q3 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q1 '25 | Q2 '25 | Q3 '25 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | -65.2% | -63.3% | -66% | -89.3% | -32.7% | -65.7% | -124.5% | -110.7% | -92% | -35.7% | -123.1% | -86.5% | -60.3% | -75.2% |
| QoQ Change | — | +2.9% | -4.3% | -35.3% | +63.4% | -100.9% | -89.5% | +11.1% | +16.9% | +61.2% | -244.8% | +29.7% | +30.3% | -24.7% |
| YoY Change | — | — | — | -37.0% | +48.3% | +0.5% | -39.4% | -238.5% | — | +71.3% | -11.2% | +6.0% | -68.9% | +38.9% |
We use cookies for analytics. See our Privacy and Cookie Policy.